367 related articles for article (PubMed ID: 9432289)
1. [Inhibitory monoamine oxidases of the new generation].
Nowakowska E; Chodera A
Pol Merkur Lekarski; 1997 Jul; 3(13):1-4. PubMed ID: 9432289
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation.
Youdim MB; Weinstock M
Neurotoxicology; 2004 Jan; 25(1-2):243-50. PubMed ID: 14697899
[TBL] [Abstract][Full Text] [Related]
3. Elucidating the mechanism of action and potential interactions of MAO-B inhibitors.
Bainbridge JL; Page RL; Ruscin JM
Neurol Clin; 2008 Aug; 26(3 Suppl):S85-96, vi. PubMed ID: 18774444
[TBL] [Abstract][Full Text] [Related]
4. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
Guay DR
Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibitors of monoamine oxidase type B and the "cheese effect".
Finberg JP; Gillman K
Int Rev Neurobiol; 2011; 100():169-90. PubMed ID: 21971008
[TBL] [Abstract][Full Text] [Related]
6. Pharmacology of MAO B inhibitors: mode of action of (-)deprenyl in Parkinson's disease.
Youdim MB
J Neural Transm Suppl; 1986; 22():91-105. PubMed ID: 3097263
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
8. Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide.
Nair NP; Ahmed SK; Kin NM
J Psychiatry Neurosci; 1993 Nov; 18(5):214-25. PubMed ID: 7905288
[TBL] [Abstract][Full Text] [Related]
9. [Monoamine oxidase inhibitors and pressor response to dietary amines].
Tipton KF
Vopr Med Khim; 1997; 43(6):494-503. PubMed ID: 9503566
[TBL] [Abstract][Full Text] [Related]
10. Psychotropic drugs (2). Interaction between monoamine oxidase (MAO) inhibitors and other substances.
Sjöqvist F
Proc R Soc Med; 1965 Nov; 58(11 Part 2):967-78. PubMed ID: 4952963
[TBL] [Abstract][Full Text] [Related]
11. Studies of selective and reversible monoamine oxidase inhibitors.
Mann JJ; Aarons SF; Frances AJ; Brown RD
J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):62-6. PubMed ID: 6429130
[TBL] [Abstract][Full Text] [Related]
12. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
[TBL] [Abstract][Full Text] [Related]
13. The effect of various monoamine oxidase (MAO) inhibitors on the response of blood pressure of rats and cats to tyramine.
Abdo-Rubo A
Acta Physiol Hung; 1990; 75(4):321-36. PubMed ID: 2127505
[TBL] [Abstract][Full Text] [Related]
14. (-)-Trans-epsilon-viniferin, a polyphenol present in wines, is an inhibitor of noradrenaline and 5-hydroxytryptamine uptake and of monoamine oxidase activity.
Yáñez M; Fraiz N; Cano E; Orallo F
Eur J Pharmacol; 2006 Aug; 542(1-3):54-60. PubMed ID: 16828740
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of monoamine oxidase by indole and benzofuran derivatives.
Prins LH; Petzer JP; Malan SF
Eur J Med Chem; 2010 Oct; 45(10):4458-66. PubMed ID: 20674099
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson's disease?
Tabakman R; Lecht S; Lazarovici P
Bioessays; 2004 Jan; 26(1):80-90. PubMed ID: 14696044
[TBL] [Abstract][Full Text] [Related]
17. Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release.
Finberg JP
Pharmacol Ther; 2014 Aug; 143(2):133-52. PubMed ID: 24607445
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy.
Löscher W; Lehmann H; Teschendorf HJ; Traut M; Gross G
J Pharmacol Exp Ther; 1999 Mar; 288(3):984-92. PubMed ID: 10027835
[TBL] [Abstract][Full Text] [Related]
19. MDL 72,974A: a selective MAO-B inhibitor with potential for treatment of Parkinson's disease.
Palfreyman MG; McDonald IA; Zreika M; Cremer G; Haegele KD; Bey P
J Neural Transm Suppl; 1993; 40():101-11. PubMed ID: 8294896
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacology of MAO inhibitors: safety and future.
Yamada M; Yasuhara H
Neurotoxicology; 2004 Jan; 25(1-2):215-21. PubMed ID: 14697896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
